GLP-1 Coverage and Prior Authorization: How to Tell What Is Happening — and What to Do

You waited weeks for your GLP-1 prescription, and then something went wrong at the pharmacy counter or in the mail: a request for “prior authorization,” a letter saying you have been moved to a different medication, or a flat “not covered.” These feel similar, but they are not the same problem — and the most common mistake is spending weeks fighting the wrong one. This guide walks through how to tell which wall you have hit and what to do about each, in plain language.

Start here: which wall did you hit?

Before you do anything else, find out whether your medication is covered with conditions or not covered at all. That single answer changes everything that follows. Two quick steps:

• Read the reason on the letter. Your prior-authorization determination letter (and sometimes your Explanation of Benefits) states a reason. Language like “requires prior authorization,” “criteria not met,” or “step therapy required” points to a covered drug with conditions. Language like “not a covered benefit,” “excluded,” or “weight-loss drugs not covered” points to an exclusion.
• Call and ask one precise question. Using the member number on your card: “Is this medication a covered benefit for my diagnosis on my plan, or is it covered but requires prior authorization?” Write down the answer and the date.

From there, you are in one of the three situations below.

If it is prior authorization: what to do this week

When the drug is covered and the question is whether your situation meets the plan's criteria, your job is to help your prescriber put the right information in front of the reviewer:

• Get the plan's written criteria. Every plan has a written coverage policy (sometimes called a utilization-management or pharmacy policy) for GLP-1s. Many insurers post these publicly on their policy pages; your prescriber's office can also pull it from the plan's provider portal, or you can call the pharmacy-benefits number on your card (often different from the medical line) and ask for “the coverage policy or PA criteria for this medication.” It tells you exactly what the reviewer is checking, so nothing is left to guesswork.
• Match your chart to those criteria. Make sure the things the policy asks for are actually documented: your diagnosis, any medications you have already tried for the same condition (with rough dates and why you stopped), relevant measurements, and recent labs. If you have a contraindication to a “try this first” medication, that should be documented too.
• Understand step therapy if it applies. If the letter says “step therapy required,” the plan wants you to try a preferred or lower-cost medication before this one. Trials you have already done can count — so make sure past medications and the reason each did not work are in your chart — and a documented contraindication or prior failure can serve as the override.
• Flag urgency when it applies. If a delay could seriously affect your health, your prescriber can mark the request expedited, which shortens the decision window.

While you wait: do not stop a GLP-1 abruptly without talking to your prescriber. Ask whether a short bridge or sample supply is available, ask the pharmacy about a one-time partial fill, and let your prescriber know if you are mid-titration — an interruption in treatment can itself support an expedited request.

How long it should take — and why your plan type decides

There is no single national deadline for a GLP-1 prior authorization. The timeline depends on the kind of insurance you have, and your decision letter or member handbook states the exact deadline that applies to you. Here is the honest picture:

If you are not sure which category you are in, ask your employer's benefits team or your plan directly whether your coverage is self-funded or fully insured — it determines which rules protect you.

If your plan switched you to a different GLP-1

When a plan moves you from one GLP-1 to another, you can ask your prescriber to request a formulary exception based on continuity of care. The strongest version of that request is simple: if you are responding well to your current medication and a switch could risk losing that progress, that is a recognized reason to ask to stay on it. The plan still makes the final decision, but “I am stable and responding on this medication” is the part that carries weight. Talk through the clinical details with your prescriber so the request reflects your actual response.

If your plan does not cover GLP-1s at all

This is the situation people most often misread — and the reason the first step in this guide is finding out whether you are excluded. When a plan does not cover GLP-1s for your use, filing medical-necessity appeals usually leads to a dead end, because the issue is what the plan chose to cover, not whether the drug is right for you. Here is what actually tends to help:

• Ask your employer's HR or benefits team, not just the insurer. If your plan is self-funded, your employer decides what is covered and the insurer only administers it. Ask whether there is a process to request an exception for a documented medical need. This is the lever many patients never pull.
• Talk with your prescriber about whether another diagnosis applies. GLP-1s are covered far more widely for conditions like type 2 diabetes, cardiovascular disease, and obstructive sleep apnea than for weight management alone. If one of these applies to you, it may open a covered pathway. This is a clinical decision to make with your provider, based on your actual health — not a workaround.
• Look at cash and manufacturer options. Manufacturers offer savings cards, income-based patient assistance programs, and direct-purchase self-pay options that have brought cash prices down from where they were — though for most people these still run several hundred dollars a month. For people with Medicare, a temporary federal program (the Medicare GLP-1 Bridge) is set to offer limited access to obesity GLP-1s at a flat $50 monthly copay starting July 2026 through 2027. These programs change often, so confirm the current terms directly with the manufacturer or Medicare before relying on them. (See what GLP-1 medications actually cost in 2026 for current cash-pay prices.)
• Look ahead to open enrollment. If a plan flatly excludes GLP-1s, the most durable fix for some people is choosing a plan that covers them at the next open enrollment — your own, a spouse's, or, where eligible, a Marketplace or Medicaid plan. Whether obesity GLP-1s are covered varies widely by state Medicaid program and by Marketplace plan, so it is worth checking the specific plan's drug list before you enroll.
• Know that “not covered” is sometimes the real answer. It is fair to be told a plan will not cover this, and it is better to learn that early than after weeks of appeals. Knowing it lets you put your energy into the paths above instead.

If a covered-benefit PA is denied: your appeal options

When the drug is covered and a prior authorization was denied on the criteria, several paths are open, and they are not mutually exclusive:

• Internal appeal. You or your prescriber submits a written appeal with additional information to a different reviewer than the one who made the first decision. Your deadline to file depends on your plan type and is stated on the denial letter — check that date and file before it.
• Peer-to-peer review. Your prescriber requests a direct conversation with the plan's medical reviewer. This is often the fastest way to resolve a denial that came down to missing context.
• External (independent) review. If internal appeals do not resolve it, many plans must offer review by an independent outside reviewer for medical-necessity denials. Standard external reviews are generally decided within about 45 days, and faster when expedited. The denial letter explains how to request it.
• State insurance department (for fully insured plans). If your plan is fully insured, your state insurance department can be a backstop — you can file a complaint or use the state's external-review process. Self-funded employer plans are not regulated by the state; there, the employer is the lever.
• Patient assistance programs. If cost is the remaining barrier, manufacturer assistance programs help patients who meet income and insurance-status criteria. Eligibility rules change, so verify directly with the manufacturer.

Background: why GLP-1s draw this much insurance attention

GLP-1 receptor agonists (semaglutide and tirzepatide are the most common) sit at the top of most plans' review lists for a few reasons: their list prices have been high, their approved uses have expanded across diabetes, weight management, cardiovascular risk, and sleep apnea, and the number of prescriptions has grown quickly. Prior authorization, step therapy, formulary changes, and, increasingly, coverage exclusions are the tools plans use to manage that. None of this is a statement about whether the medication is right for you — it is about how your specific plan is designed.